6. Keryx Biopharmaceuticals ( KERX) Company Profile: Keryx is a biopharmaceutical company with a focus on products for the treatment of life-threatening diseases, including renal disease & cancer. Share Price: $4.62 (June 27) Stock Performance This Year: 1% Analyst Consensus: Eight analysts have a "buy" rating on Keryx, including those at firms like Oppenheimer and Ladenburg Thalmann. The only other research shop following the company rates the stock a "hold." The average analyst price target of $10 represents potential upside of 103% from current levels. Bullish Case: Oppenheimer analyst Boris Peaker wrote in a June 7 research note that he is "cautiously optimistic about the ongoing Phase III trial of perifosine in late-stage colorectal cancer," and that his model suggests a price target for Keryx of $8. He bases this target on the assumption that the patent expiration set for July 2013 will be extended by five years to July 2018. TheStreet Ratings does not cover Keryx Biopharmaceuticals.